---
document_datetime: 2025-10-27 15:30:12
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/idacio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: idacio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.734582
conversion_datetime: 2025-12-24 03:22:45.014693
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Idacio

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                             |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0024/G            | This was an application for a group of variations. 1. Type II - B.I.a.2.c - Changes to the manufacturing process of the biological/immunological active substance (AS) adalimumab to replace the current manufacturing process Version A by the new | 18/09/2025                          |                                             | SmPC, Labelling and PL           | The SmPC has been updated as follows: Section 4.2: changes have been introduced in relation to the withdraw the vial presentation (EU/1/19/1356/001) indicated for paediatric use. Section 4.4: a new warning has been introduced for the presence of polysorbates. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| upstream manufacturing process Version C (slight decreasing in the pH and post-shift temperature setpoints and increasing in the cell culture duration in the production bioreactor). The change is consequential to the change in the AS excipients (from a Citrate-based to an Acetate-based formulation), with related changes in the AS release and shelf-life specifications (primarily to adapt to the adjusted glycan profile, and to reflect the accumulated history of batch data for osmolality, oxidized forms, HMW related substances, and electrophoretic purity) and in the shelf-life for AS (C/Acetate) from 36 to 48 months when stored at the long-term storage conditions of -80°C ± 10°C. 2. Type IA - B.I.a.4.b - To update the AS mycoplasma in-process test (from FDA CBER/PTC 1993 to culture method according to USP 63 and EP 2.6.7). 3. Type II - B.II.a.3.b.3 - Changes in the composition of the biological finished product (FP- Idacio) to replace the currently approved Idacio Citrate-based formulation with a new Acetate based formulation, with consequential changes to the FP release and/or shelf-life specifications (additionally the specifications are updated to reflect the accumulated history of batch data for osmolality, charge variants, oxidized forms, deamidated forms, HMW related substance, LMW fragments, and electrophoretic purity) and on the shelf-life for PS (C/Acetate) from 24 months to 36 months at the long-term storage condition (5°C± 3°C), with   | Section 6.1: the list of excipients has been updated to reflect the new formulation Section 6.3: the shelf life has been increased from 2 to years The SmPC for EU/1/19/1356/001 vial presentation for paediatric use has been removed. For more information, please refer to the Summary of Product Characteristics. The labelling and Package Leaflet have been updated accordingly.   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | List of Excipients, SmPC for PFS/pen Section 6.3 Shelf-life, Outer Carton for PFS & pen Section 3 List of excipients, Package Leaflet for PFS & pen Section 6 What Idacio contains) and to the RMP. The change is supported by clinical data. 4. Type IA - B.II.e.5.b. to withdraw the vial presentation (EU/1/19/1356/001) consequent to business reasons, with consequential changes to the PI. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.II.a.3.b.3 - Changes in the composition (excipients) of the finished product - Other excipients - Change that relates to a biological/immunological product B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal   |            |            |      |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| IB/0023 | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/10/2024 | 17/09/2025 | SmPC |

<div style=\"page-break-after: always\"></div>

| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/09/2023   | 30/10/2023   | SmPC and PL   | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Idacio in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10783 /202212 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                                                                                                                                                                                                                   | 31/08/2023   | n/a          |               | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| II/0018/G           | This was an application for a group of variations. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting | 15/06/2023   | n/a          |               |                                                                                                                                                                                                                                                                        |
| IB/0020             | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                 | 16/03/2023   | n/a          |               |                                                                                                                                                                                                                                                                        |
| IB/0019/G           | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.z - Replacement or addition of a                                                                                                                                                                                                                                                                                                     | 22/02/2023   | n/a          |               |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| II/0017   | Submission of an updated RMP version 6 in order to propose a continuation of the observational registry (RABBIT) Study #1 (Study Identifier: FKS0-000- RAB) and the cancelation of the observational registry (IBD UK) (Study Identifier: FKS0-000-IBD). In addition, the MAH took the opportunity to align the RMP with the current approved RMP of the reference product. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH significant assessment is required   | 29/09/2022   | n/a        |             | where   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------|
| IB/0016   | B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 08/03/2022   | n/a        |             |         |
| IB/0015   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/01/2022   | n/a        |             |         |
| IAIN/0014 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 08/10/2021   | n/a        |             |         |
| IB/0013   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/09/2021   | 22/10/2021 | SmPC and PL |         |

<div style=\"page-break-after: always\"></div>

|           | new additional data is required to be submitted by the MAH                                                                                                                                                                                 |            |            |                 |                                                                                                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------|
| IB/0012   | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                | 22/07/2021 | n/a        |                 |                                                                                                       |
| IB/0011/G | This was an application for a group of variations. B.II.b.2.z - Change to importer, batch release arrangements and quality control testing of the FP - Other variation A.7 - Administrative change - Deletion of manufacturing sites       | 05/07/2021 | 22/10/2021 | Annex II and PL |                                                                                                       |
| IB/0009   | B.II.f.z - Stability of FP - Other variation                                                                                                                                                                                               | 09/06/2021 | 22/10/2021 | SmPC and PL     | Update of section 6.4 of the Summary of Product Characteristics and section 5 of the Package Leaflet. |
| IB/0010   | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority | 26/05/2021 | 22/10/2021 | SmPC and PL     |                                                                                                       |
| II/0007   | B.I.e.2.z - Design Space - Introduction of a post approval change management protocol related to the AS - Other variation                                                                                                                  | 14/01/2021 | n/a        |                 |                                                                                                       |
| IB/0008   | C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of                                           | 21/10/2020 | 22/10/2021 | SmPC and PL     |                                                                                                       |

<div style=\"page-break-after: always\"></div>

|                     | wording agreed by the competent authority                                                                                                                                                                                                                                                          |            |            |                        |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0006/G           | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 03/09/2020 | n/a        |                        |                                   |
| PSUSA/10783 /201912 | Periodic Safety Update EU Single assessment - adalimumab                                                                                                                                                                                                                                           | 03/09/2020 | n/a        |                        | PRAC Recommendation - maintenance |
| IB/0004             | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                       | 19/12/2019 | 18/06/2020 | SmPC                   |                                   |
| WS/1651             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation        | 03/10/2019 | 18/06/2020 | Annex II               |                                   |
| WS/1652/G           | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                            | 25/07/2019 | 18/06/2020 | SmPC, Labelling and PL |                                   |

<div style=\"page-break-after: always\"></div>

|             | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes                                                                                                                                                                                                                          |            |            |                 |     |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----|
| IAIN/0001/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - including batch control/testing | 12/06/2019 | 18/06/2020 | Annex II and PL | Not |